Concomitantly, inhibition of hepatic apoA5 secretion led to hepatocyte apoA5 retention, which facilitates the biogenesis of triglyceride-rich lipid droplets and consequently NAFLD development. The gene discussed is APOA5; the disease is metabolic dysfunction-associated steatotic liver disease.